# US 2019/0169634 A1 · Genetic erasers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169634 A1
- Document ID: US20190169634A1
- Status: Published application
- Kind: A1
- Application number: 16/319,786
- Filed: 2017-07-26
- Published: 2019-06-06
- Earliest claimed: 2016-07-26
- Assignees: Senti Biosciences, Inc.
- Applicants: Senti Biosciences, Inc.
- Inventors: Timothy Kuan-Ta Lu; Remus Wong
- Web page: https://patentgrep.com/patent/US20190169634A1

## CPC

- C12N 15/86: Viral vectors
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/67: General methods for enhancing the expression
- C12N 15/85: for animal cells
- C12N 2310/122: Hairpin
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/24: Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/30: being an enhancer not forming part of the promoter region
- C12N 2840/105: enhancing translation
- C12Y 301/21: Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided herein, in some embodiments, are methods, compositions, systems and kits that enable removal of heterologous nucleic acid from engineered cells.

## Claims

### Claim 1

An engineered genetic construct comprising a cassette that comprises (a) a nucleotide sequence encoding a first product of interest, and (b) a nucleotide sequence encoding a second product of interest and a counterselectable marker, wherein expression or activity of the first product of interest is activatable, and wherein the first product of interest modulates excision or degradation of the cassette.

### Claim 2 (depends on 1)

The engineered genetic construct of claim 1, wherein the first product of interest is a recombinase.

### Claim 3 (depends on 2)

The engineered genetic construct of claim 2, wherein the recombinase is a ligand-dependent chimeric recombinase.

### Claim 4 (depends on 3)

The engineered genetic construct of claim 3, wherein the ligand-dependent chimeric recombinase is linked to a mutated human estrogen receptor (ER) ligand binding domain.

### Claim 5 (depends on 3)

The engineered genetic construct of claim 3, wherein the recombinase is a split-recombinase that includes a first fragment and a second fragment that when combined form the recombinase.

### Claim 6 (depends on 5)

The engineered cell of claim 5, wherein dimerization of the first fragment and the second fragment is inducible.

### Claim 7 (depends on 5)

The engineered cell of claim 5, wherein the first fragment is linked to a FKBP domain and the second fragment is linked to FRB domain.

### Claim 8 (depends on 2)

The engineered genetic construct of claim 2, wherein the recombinase is selected from tyrosine recombinases and tyrosine integrases.

### Claim 9 (depends on 8)

The engineered genetic construct of claim 8, wherein the recombinase is a tyrosine recombinase selected from Cre, Dre, Flp, KD, B2, B3, λ, HK022 and HP1 recombinases.

### Claim 10 (depends on 2)

The engineered genetic construct of any one of claim 2, wherein the recombinase(s) is selected from serine recombinases and serine integrases.

### Claim 11 (depends on 10)

The engineered genetic construct of claim 10, wherein the recombinase is selected from γ6, ParA, Tn3, Gin, ΦC31, Bxb1 and R4 recombinases.

### Claim 12 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The engineered genetic construct of any one of claims 2-11, wherein the cassette is flanked by cognate recombinase recognition sites.

### Claim 13 (depends on 1)

The engineered genetic construct of claim 1, wherein the first product of interest is a nuclease.

### Claim 14 (depends on 13)

The engineered genetic construct of claim 13, wherein the nuclease is selected from meganucleases, RNA-guided nucleases, zinc-finger nucleases, and transcription activator-like effector nucleases.

### Claim 15 (depends on 14)

The engineered genetic construct of claim 14, wherein the nuclease is a meganuclease selected from intron endonucleases and intein endonucleases.

### Claim 16 (depends on 14)

The engineered genetic construct of claim 14, wherein the nuclease is a RNA-guided nuclease selected from Cas9 nucleases and Cpf1 nucleases.

### Claim 17 (depends on 16)

The engineered genetic construct of claim 16, wherein the cassette further comprises nucleotide sequences encoding guide RNAs (gRNAs) complementary to the nuclease recognitions sites.

### Claim 18 (depends on 13, 14, 15, 16, 17)

The engineered genetic construct of any one of claims 13-17, wherein the cassette comprises cognate nuclease recognition sites.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The engineered genetic construct of any one of claims 1-18, wherein the nucleotide sequence of (a) is operably linked to an inducible promoter.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The engineered genetic construct of any one of claims 1-19, wherein the nucleotide sequence of (b) is operably lined to a constitutive promoter.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The engineered genetic construct of any one of claims 1-18, wherein the nucleotide sequenced of (a) and (b) are operably linked to a single constitutive promoter.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The engineered genetic construct of any one of claims 1-21, wherein the second product of interest is a therapeutic molecule or a prophylactic molecule.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The engineered genetic construct of any one of claims 1-22, wherein the product of interest is a protein, peptide or nucleic acid.

### Claim 24 (depends on 23)

The engineered genetic construct of claim 23, wherein the product of interest is a nucleic acid selected from RNA, DNA or a combination of RNA and DNA.

### Claim 25 (depends on 24)

The engineered genetic construct of claim 24, wherein product of interest is a RNA selected from short-hairpin RNAs, short interfering RNAs and micro RNAs.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The engineered genetic construct of any one of claims 1-25, wherein the counterselectable marker is a prodrug.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The engineered genetic construct of any one of claims 1-25, wherein the counterselectable marker is selected from cytosine deaminases and thymidine kinases

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A vector comprising the engineered genetic construct of any one of claims 1-27, optionally wherein the vector is a plasmid or a viral vector.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A cell comprising the engineered genetic construct of any one of claims 1-27 or the vector of claim 28.

### Claim 30 (depends on 29)

The cell of claim 29, wherein the cell is a stem cell or an immune cell.

### Claim 31 (depends on 30)

The cell of claim 30, wherein the cell is a stem cell selected from mesenchymal stem cells, hematopoietic stem cells, embryonic stem cells, and pluripotent stem cells.

### Claim 32 (depends on 30)

The cell of claim 30, wherein the cell is an immune cell selected from natural killer (NK) cells, NKT cells, mast cells, eosinophils, basophils, macrophages, neutrophils, dendritic cells, T cells and B cells.

### Claim 33 (depends on 32)

The cell of claim 32, wherein the cell is a T cell selected from CD8+ T cells, CD4+ T cells, gamma-delta T cells, and T regulatory cells.

### Claim 34 (depends on 32, 33)

The cell of claim 32 or 33, wherein the T cell is a chimeric antigen receptor (CAR) T cell or an engineered T cell receptor (TCR) cell.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A composition comprising the engineered genetic construct of any one of claims 1-27, the vector of claim 28, or the cell of any one of claims 29-34.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A kit comprising the engineered genetic construct of any one of claims 1-27 or the vector of claim 28 and at least one inducer agent and/or counterselective agent.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method comprising introducing into a population of cells the engineered genetic construct of any one of claims 1-27 or the vector of claim 28.

### Claim 38 (depends on 29, 30, 31, 32, 33, 34)

A method of delivering to a subject the cell of any one of claims 29-34.

### Claim 39

An engineered genetic construct comprising a cassette that comprises:
(a) an inducible promoter operably linked to a nucleotide sequence encoding a recombinase; and
(b) a promoter operably linked to a nucleotide sequence encoding a product of interest and a counterselectable marker,
wherein the cassette is flanked by cognate recombinase recognition sites.

### Claim 40 (depends on 39)

The engineered genetic construct of claim 39, wherein (a) is upstream from (b).

### Claim 41 (depends on 39, 40)

The engineered genetic construct of claim 39 or 40, wherein a terminator sequence is located between (a) and (b).

### Claim 42 (depends on 39, 40, 41)

The engineered genetic construct of any one of claims 39-41, wherein (a) comprises at least two inducible promoters, each linked to a different recombinase, and wherein the cassette is flanked by recombinase recognition sites cognate to the different recombinases.

### Claim 43 (depends on 39, 40, 41)

The engineered genetic construct of any one of claims 39-41, wherein the nucleotide sequence of (a) encodes at least two different recombinases, and wherein the cassette is flanked by recombinase recognition sites cognate to the different recombinases.

### Claim 44 (depends on 39, 40, 41, 42, 43)

The engineered genetic construct of any one of claims 39-43, wherein the nucleotide sequence of (b) encodes at least two counterselectable markers.

### Claim 45 (depends on 39, 40, 41, 42, 43, 44)

The engineered genetic construct of any one of claims 39-44, wherein the recombinase(s) is selected from tyrosine recombinases and tyrosine integrases.

### Claim 46 (depends on 45)

The engineered genetic construct of claim 45, wherein the recombinase(s) is selected from Cre, Dre, Flp, KD, B2, B3, λ, HK022 and HP1 recombinases.

### Claim 47 (depends on 39, 40, 41, 42, 43, 44, 45, 46)

The engineered genetic construct of any one of claims 39-46, wherein the recombinase(s) is selected from serine recombinases or serine integrases.

### Claim 48 (depends on 47)

The engineered genetic construct of claim 47, wherein the recombinase(s) is selected from γδ, ParA, Tn3, Gin, ΦC31, Bxb1 and R4 recombinases.

### Claim 49 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The engineered genetic construct of any one of claims 39-48, wherein the product of interest is a therapeutic molecule or a prophylactic molecule.

### Claim 50 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The engineered genetic construct of any one of claims 39-49, wherein the product of interest is a protein, peptide or nucleic acid.

### Claim 51 (depends on 50)

The engineered genetic construct of claim 50, wherein the product of interest is a nucleic acid selected from RNA, DNA or a combination of RNA and DNA.

### Claim 52 (depends on 51)

The engineered genetic construct of claim 51, wherein product of interest is a RNA selected from short-hairpin RNAs, short interfering RNAs and micro RNAs.

### Claim 53 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The engineered genetic construct of any one of claims 39-52, wherein the counterselectable marker is a prodrug.

### Claim 54 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The engineered genetic construct of any one of claims 39-52, wherein the counterselectable marker is selected from cytosine deaminases and thymidine kinases.

### Claim 55 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A vector comprising the engineered genetic construct of any one of claims 39-54, optionally wherein the vector is a plasmid or a viral vector.

### Claim 56 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A cell comprising the engineered genetic construct of any one of claims 39-54 or the vector of claim 55.

### Claim 57 (depends on 56)

The cell of claim 56, wherein the cell is a stem cell or an immune cell.

### Claim 58 (depends on 57)

The cell of claim 57, wherein the cell is a stem cell selected from a mesenchymal stems, hematopoietic stem cells, embryonic stem cells, and pluripotent stem cells.

### Claim 59 (depends on 57)

The cell of claim 57, wherein the cell is an immune cell selected from natural killer (NK) cells, NKT cells, mast cells, eosinophils, basophils, macrophages, neutrophils, dendritic cells, T cells and B cells.

### Claim 60 (depends on 59)

The cell of claim 59, wherein the cell is a T cell selected from CD8+ T cells, CD4+ T cells, gamma-delta T cells, and T regulatory cells.

### Claim 61 (depends on 59, 60)

The cell of claim 59 or 60, wherein the T cell is a chimeric antigen receptor (CAR) T cell or an engineered T cell receptor (TCR) cell.

### Claim 62 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

A composition comprising the engineered genetic construct of any one of claims 39-54, the vector of claim 55, or the cell of any one of claims 56-61.

### Claim 63 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A kit comprising the engineered genetic construct of any one of claims 39-54 or the vector of claim 55 and at least one inducer agent that modulates activity of the inducible promoter(s) of (a).

### Claim 64 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

A method comprising introducing into a population of cells the engineered genetic construct of any one of claims 39-55 or the vector of claim 56, wherein the product of interest aids in differentiation, expansion or phenotypic maintenance (persistence) of the cells.

### Claim 65 (depends on 64)

The method of claim 64 further comprising culturing cells of the population and producing the product of interest.

### Claim 66 (depends on 65)

The method of claim 65 further comprising culturing cells of the population in the presence of an inducer agent, activating the promoter of (a), expressing the recombinase(s) and excising the cassette from the engineered genetic construct.

### Claim 67 (depends on 66)

The method of claim 66 further comprising culturing cells of the population in the presence of a counterselective agent and killing cells that express the counterselectable marker.

### Claim 68 (depends on 67)

The method of claim 67, wherein less than 10% of the cells of the population comprise the cassette following the step of culturing cells of the population in the presence of a counterselective agent.

### Claim 69 (depends on 67)

The method of claim 67 further comprising delivering cells of the population to a subject.

### Claim 70 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

A method comprising introducing into a population of cells the engineered genetic construct of any one of claims 36-55 or the vector of claim 56, wherein the product of interest aids is a therapeutic molecule and/or a prophylactic molecule.

### Claim 71 (depends on 70)

The method of claim 70 further comprising delivering cells of the population to a subject.

### Claim 72 (depends on 71)

The method of claim 71 further comprising exposing the subject to an inducer agent, activating the promoter of (a), expressing the recombinase(s) and excising the cassette from the engineered genetic construct.

### Claim 73 (depends on 72)

The method of claim 72 further comprising exposing the subject to a counterselective agent and killing cells that express the counterselectable marker.

### Claim 74 (depends on 73)

The method of claim 73, wherein less than 10% of the cells of the population comprise the cassette following the step of exposing the subject to a counterselective agent.

### Claim 75 (depends on 56, 57, 58, 59, 60, 61)

A method comprising delivering to a subject the cell of any one of claims 56-61.

### Claim 76

An engineered genetic construct comprising a cassette that comprises:
(a) an inducible promoter operably linked to a nucleotide sequence encoding a nuclease; and
(b) a promoter operably linked to a nucleotide sequence encoding a product of interest and a counterselectable marker,
wherein the cassette comprises cognate nuclease recognition sites, optionally flanking the cassette.

### Claim 77 (depends on 76)

The engineered genetic construct of claim 76, wherein (a) is upstream from (b).

### Claim 78 (depends on 76, 77)

The engineered genetic construct of claim 76 or 77, wherein a terminator sequence is located between (a) and (b).

### Claim 79 (depends on 76, 77, 78)

The engineered genetic construct of any one of claims 76-78, wherein (a) comprises at least two inducible promoters, each linked to a different nuclease, and wherein the cassette comprises nuclease recognition sites cognate to the different nucleases.

### Claim 80 (depends on 76, 77, 78, 79)

The engineered genetic construct of any one of claims 76-79, wherein the nucleotide sequence of (a) encodes at least two different nucleases, and wherein the cassette comprises nuclease recognition sites cognate to the different nucleases.

### Claim 81 (depends on 76, 77, 78, 79, 80)

The engineered genetic construct of any one of claims 76-80, wherein the nucleotide sequence of (b) encodes at least two counterselectable markers.

### Claim 82 (depends on 76, 77, 78, 79, 80, 81)

The engineered genetic construct of any one of claims 76-81, wherein the nuclease(s) is selected from meganucleases, RNA-guided nucleases, zinc-finger nucleases, and transcription activator-like effector nucleases.

### Claim 83 (depends on 82)

The engineered genetic construct of claim 82, wherein the nuclease(s) is a meganuclease selected from intron endonucleases and intein endonucleases.

### Claim 84 (depends on 82)

The engineered genetic construct of claim 82, wherein the nuclease(s) is a RNA-guided nuclease selected from Cas9 nucleases and Cpf1 nucleases.

### Claim 85 (depends on 84)

The engineered genetic construct of claim 84, wherein the cassette further comprises nucleotide sequences encoding guide RNAs (gRNAs) complementary to the nuclease recognitions sites.

### Claim 86 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The engineered genetic construct of any one of claims 76-85, wherein the product of interest is a therapeutic molecule or a prophylactic molecule.

### Claim 87 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The engineered genetic construct of any one of claims 76-86, wherein the product of interest is a protein, peptide or nucleic acid.

### Claim 88 (depends on 87)

The engineered genetic construct of claim 87, wherein the product of interest is a nucleic acid selected from RNA, DNA or a combination of RNA and DNA.

### Claim 89 (depends on 88)

The engineered genetic construct of claim 88, wherein product of interest is a RNA selected from short-hairpin RNAs, short interfering RNAs and micro RNAs.

### Claim 90 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The engineered genetic construct of any one of claims 76-89, wherein the counterselectable marker is a prodrug.

### Claim 91 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The engineered genetic construct of any one of claims 76-89, wherein the counterselectable marker is selected from cytosine deaminases and thymidine kinases.

### Claim 92 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

A vector comprising the engineered genetic construct of any one of claims 76-91, optionally wherein the vector is a plasmid or a viral vector.

### Claim 93 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

A cell comprising the engineered genetic construct of any one of claims 76-91 or the vector of claim 92.

### Claim 94 (depends on 93)

The cell of claim 93, wherein the cell is a stem cell or an immune cell.

### Claim 95 (depends on 94)

The cell of claim 94, wherein the cell is a stem cell selected from mesenchymal stem cells, hematopoietic stem cells, embryonic stem cells, and pluripotent stem cells.

### Claim 96 (depends on 94)

The cell of claim 94, wherein the cell is an immune cell selected from natural killer (NK) cells, NKT cells, mast cells, eosinophils, basophils, macrophages, neutrophils, dendritic cells, T cells and B cells.

### Claim 97 (depends on 96)

The cell of claim 96, wherein the cell is a T cell selected from CD8+ T cells, CD4+ T cells, gamma-delta T cells, and T regulatory cells.

### Claim 98 (depends on 96, 97)

The cell of claim 96 or 97, wherein the T cell is a chimeric antigen receptor (CAR) T cell or an engineered T cell receptor (TCR) cell.

### Claim 99 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

A composition comprising the engineered genetic construct of any one of claims 76-91, the vector of claim 92, or the cell of any one of claims 93-98.

### Claim 100 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

A kit comprising the engineered genetic construct of any one of claims 76-91 or the vector of claim 92 and at least one inducer agent that modulates activity of the inducible promoter(s) of (a).

### Claim 101 (depends on 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

A method comprising introducing into a population of cells the engineered genetic construct of any one of claims 76-91 or the vector of claim 92, wherein the product of interest aids in differentiation, expansion or phenotypic maintenance (persistence) of the cells.

### Claim 102 (depends on 101)

The method of claim 101 further comprising culturing cells of the population and producing the product of interest.

### Claim 103 (depends on 102)

The method of claim 102 further comprising culturing cells of the population in the presence of an inducer agent, activating the promoter of (a), expressing the recombinase(s) and excising the cassette from the engineered genetic construct.

### Claim 104 (depends on 103)

The method of claim 103 further comprising culturing cells of the population in the presence of a counterselective agent and killing cells that express the counterselectable marker.

### Claim 105 (depends on 104)

The method of claim 104, wherein less than 10% of the cells of the population comprise the cassette following the step of culturing cells of the population in the presence of a counterselective agent.

### Claim 106 (depends on 104)

The method of claim 104 further comprising delivering cells of the population to a subject.

### Claim 107 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

A method comprising introducing into a population of cells the engineered genetic construct of any one of claims 39-55 or the vector of claim 56, wherein the product of interest aids is a therapeutic molecule and/or a prophylactic molecule.

### Claim 108 (depends on 107)

The method of claim 107 further comprising delivering cells of the population to a subject.

### Claim 109 (depends on 108)

The method of claim 108 further comprising exposing the subject to an inducer agent, activating the promoter of (a), expressing the recombinase(s) and excising the cassette from the engineered genetic construct.

### Claim 110 (depends on 109)

The method of claim 109 further comprising exposing the subject to a counterselective agent and killing cells that express the counterselectable marker.

### Claim 111 (depends on 110)

The method of claim 110, wherein less than 10% of the cells of the population comprise the cassette following the step of exposing the subject to a counterselective agent.

### Claim 112 (depends on 93, 94, 95, 96, 97, 98)

A method comprising delivering to a subject the cell of any one of claims 93-98.

### Claim 113

An engineered genetic construct comprising a cassette that comprises:
(a) at least one promoter operably linked to at least one nucleotide sequence encoding at least one ligand-dependent chimeric recombinase; and
(b) at least one promoter operably linked to a nucleotide sequence encoding a product of interest and a counterselectable molecule,
wherein the cassette is flanked by cognate recombinase recognition sites.

### Claim 114 (depends on 113)

The engineered genetic construct of claim 113, wherein the ligand-dependent chimeric recombinase is linked to a mutated human estrogen receptor (ER) ligand binding domain.

### Claim 115 (depends on 113, 114)

A cell comprising the engineered genetic construct of any one of claims 113 and 114.

### Claim 116 (depends on 115)

A method comprising delivering to a subject the cell of claim 115.

### Claim 117

An engineered genetic construct comprising a cassette that comprises:
(a) a promoter operably linked to a nucleotide sequence encoding a first fragment of a recombinase;
(b) a promoter operably linked to a nucleotide sequence encoding a second fragment of a recombinase, wherein the first fragment and the second fragment when combined form a full-length functional recombinase; and
(c) a promoter operably linked to a nucleotide sequence encoding a product of interest and a counterselectable marker,
wherein the cassette is flanked by cognate recombinase recognition sites.

### Claim 118 (depends on 117)

The engineered cell of claim 117, wherein the first fragment is linked to a FKBP domain and the second fragment is linked to FRB domain.

### Claim 119 (depends on 117, 118)

A cell comprising the engineered genetic construct of claim 117 or 118.

### Claim 120 (depends on 119)

A method comprising delivering to a subject the cell of claim 119.
